Pluviaendo Visuals Pluviaendo Visuals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIORCHESTRA, Presenting Lead Candidate BMD-001 for Alzheimer's disease and Drug Delivery System Technology at the 2022 BIO International Convention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$861.0 million","upfrontCash":"Undisclosed","newsHeadline":"BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Biorchestra

    Menu

    Biorchestra

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Biorchestra

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

              Details:

              Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.

              Lead Product(s): BMD-001

              Therapeutic Area: Neurology Product Name: BMD-001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $861.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biorchestra

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIORCHESTRA, Presenting Lead Candidate BMD-001 for Alzheimer's disease and Drug Delivery System Technology at the 2022 BIO International Convention

              Details:

              BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation and neurodegeneration.

              Lead Product(s): BMD-001

              Therapeutic Area: Neurology Product Name: BMD-001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biorchestra

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics

              Details:

              Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.

              Lead Product(s): Antisense Oligonucleotides

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: SK Biopharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY